A
Alcista
Alcista · 25%VRTX
$566.33
Precio del escenario
$498.500
+13.659 (+2.74%)Al cierre
Loading chart…
- Máximo
- 502.935
- Apertura
- 490.450
- Precio medio ponderado por volumen
- 496.32
- Volumen
- 2.09M
- Capitalización
- 121.93B
- Mínimo
- 487.540
- Importe
- 1.04B
- EV/EBITDA, TTM
- 20.58
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The Company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, acute pain and acromegaly, and it continues to advance clinical and research programs in these areas. It also has a clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, congenital adrenal hyperplasia, ACTH-dependent Cushing's syndrome, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1. The Company's pipeline also includes PALSONIFY (paltusotine) and atumelnant. PALSONIFY is the once-daily oral therapy for acromegaly.
Análisis de IA of Vertex Pharmaceuticals Inc (VRTX)
ComprarVertex Pharmaceuticals is a good buy right now due to its strong revenue growth and positive analyst ratings. The current price is $510.08, with a forward P/E ratio of 24.0964, indicating potential for future earnings growth. Additionally, the gross margin stands at an impressive 85.33%, showcasing the company's profitability. However, insider selling has increased by 753.33%, which is a risk to consider.
Recomendaciones de analistas (27)
+3.49% de potencial alcista
Comprar
22 Comprar
5 Mantener
0 Vender
Actual: 498.50
Mínimo
414.00
Promedio
515.88
Máximo
604.00
BofA
Comprar
$667
2026-10-12
BofA
2026-10-12
Precio objetivo
$667
Comprar
RBC Capital
Superar al mercado
$576
2026-10-08
RBC Capital
2026-10-08
Precio objetivo
$576
Superar al mercado
UBS
Comprar
$615
2026-09-29
UBS
2026-09-29
Precio objetivo
$615
Comprar
UBS
Comprar
$615
2026-09-28
UBS
2026-09-28
Precio objetivo
$615
Comprar
JPMorgan
Sobreponderar
$560
2026-09-11
JPMorgan
2026-09-11
Precio objetivo
$560
Sobreponderar
Métricas de valoración
El PER previsto actual de Vertex Pharmaceuticals Inc (VRTX) es 24.10, frente a su media de 5 años de 187.76.
Escenarios de precio de Alphio AI para VRTX
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con VRTX en cartera
Cronología de eventos
Noticias
8.510-15FoolVertex Pharmaceuticals Acquires Crinetics, Ushering in a New Era
6.510-13FoolComparative Analysis of Moderna and Vertex Pharmaceuticals
9.010-09NewsfilterALYFTREK Shows Pancreatic Function Recovery in Young CF Patients
5.010-09FoolCRISPR Therapeutics' New Drug Approval Sparks Optimism for Stock Price
7.510-09CNBCEmily's Entourage Drives Hope for Cystic Fibrosis Patients
Preguntas frecuentes sobre VRTX, respondidas por Alphio AI
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The Company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, acute pain and acromegaly, and it continues to advance clinical and research programs in these areas. It also has a clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, congenital adrenal hyperplasia, ACTH-dependent Cushing's syndrome, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1. The Company's pipeline also includes PALSONIFY (paltusotine) and atumelnant. PALSONIFY is the once-daily oral therapy for acromegaly. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Vertex Pharmaceuticals is a good buy right now due to its strong revenue growth and positive analyst ratings. The current price is $510.08, with a forward P/E ratio of 24.0964, indicating potential for future earnings growth. Additionally, the gross margin stands at an impressive 85.33%, showcasing the company's profitability. However, insider selling has increased by 753.33%, which is a risk to consider.
27 analysts cover VRTX: 22 rate it Buy, 5 Hold and 0 Sell. The average price target is 515.88.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.